BOTHELL, Wash., July 10 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics announced today that Alton Boynton, Ph.D. company President will present an update on the Company’s late stage clinical trials for brain and prostate cancer, recent FDA clearances of two additional INDs for multiple additional cancers (including lung cancer), and ongoing long-term survival data from the Company’s prior early stage clinical trials. The presentation will take place July 11 at 3:56 PM Eastern Time at the CE Unterberg, Towbin Emerging Growth Conference. The conference is being held at the Mandarin Oriental Hotel in New York City.
The presentation will be webcast live and available for replay for 90 days from the Northwest Biotherapeutics website, www.nwbio.com under the “Investor and Media” section.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company’s three lead product candidates are:
DCVax(R)-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax(R)-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and CXCR4 a therapeutic monoclonal antibody in late preclinical development for the treatment of cancer. For further information, please visit the company web site at www.nwbio.com.
Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expects,” “believes,” “intends,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in the planned Phase III trial of DCVax(R)-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax-Prostate will demonstrate safety and efficacy, risks associated with the planned Phase II clinical trial of DCVax(R)-Brain and the planned Phase I clinical trial for non-small cell lung cancer and head and neck cancer, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company’s results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially those projected in any forward- looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Northwest Biotherapeutics
CONTACT: Lorie Calvo, +1-425-608-3008
Web site: http://www.nwbio.com//
